GENEVA—The potential for using vaccines as important weapons against non small cell lung cancer has not yet been realized according to Johan Vansteenkiste MD PhD, an oncologist and professor of medicine at University Hospitals Leuven in Belgium. After his talk at the 2015 European Lung Cancer Conference he told Oncology Times reporter Peter Goodwin that his group’s findings in the MAGRIT trial using the MAGE-A3 vaccine did not raise hopes that vaccination could yet be regarded as an independent therapy but that combining immune-based therapies—to include the so-called: “check point inhibitors” and release the brakes on natural immunity imposed by cancer—could be an enabling strategy.
You may also like...
Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds 6 Feb, 2014 Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia 6 Aug, 2013 Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome 27 Mar, 2015 Breast Cancer Prognostic Implications of Obesity and Insulin Resistance 28 Mar, 2015
- Previous story Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed
- Next story Controlling Side Effects from Targeted Drugs in Lung Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014